Oxaliplatin: A Review of Evolving Concepts

REFERENCES

• Burchenal J.H., Kalaher K., O'Toole T., Chisholm J. Lack of Cross-Resistance Between Certain Platinum Coordination Compounds in Mouse Leukemia. Cancer Res. 1977; 37: 3455–3457
   PubMed Web of Science ®Google Scholar
• Gibbons G.R., Page J.D., Mauldin S.K., Husain I., Chaney S.G. Role of Carrier Ligand in Platinum Resistance in L1210 Cells. Cancer Res. 1990; 50: 6497–6501
   PubMed Web of Science ®Google Scholar
• Schmidt W., Chaney S.G. Role of Carrier Ligand in Platinum Resistance of Human Carcinoma Cell Lines. Cancer Res. 1993; 53: 799–805
   PubMed Web of Science ®Google Scholar
• Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., Hamilton T.C., Chaney S.G. The Role of hMLH1, hMSH3, and hMSH6 Defects in Cisplatin and Oxaliplatin Resistance: Correlation with Replicative Bypass of Platinum-DNA Adducts. Cancer Res. 1998; 58: 3579–3585
   PubMed Web of Science ®Google Scholar
• Jennerwein M.M., Eastman A., Khokhar A.R. Characterization of Adducts Produced in DNA by Isomeric 1,2-Diaminocyclohexaneplatinum(II) Complexes. Chem.-Biol. Interact. 1989; 70: 39–49
   PubMed Web of Science ®Google Scholar
• Page J.D., Husain I., Sancar A., Chaney S.G. Effect of the Diaminocyclohexane Carrier Ligand on Platinum Adduct Formation, Repair, and Lethality. Biochemistry 1990; 29: 1016–1024
   PubMed Web of Science ®Google Scholar
• Saris C.P., van de Vaart P.J.M., Rietbroek R.C., Blommaert F.A. In Vitro Formation of DNA Adducts by Cisplatin, Lobaplatin and Oxaliplatin in Calf Thymus DNA in Solution and in Cultured Human Cells. Carcinogenesis 1996; 17: 2763–2769
   PubMed Web of Science ®Google Scholar
• Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C.S., Juniewicz P. Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA. Mol. Pharmacol. 1998; 54: 770–777
   PubMed Web of Science ®Google Scholar
• Scheeff E.D., Briggs J.M., Howell S.B. Molecular Modeling of the Intrastrand Guanine–Guanine DNA Adducts Produced by Cisplatin and Oxaliplatin. Mol. Pharmacol. 1999; 56: 633–643
   PubMed Web of Science ®Google Scholar
• Gelasco A., Lippard S.J. NMR Solution Structure of a DNA Dodecamer Duplex Containing a cis-Diammineplatinum(II) dGpG Intrastrand Cross-Link, the Major Adduct of the Anticancer Drug Cisplatin. Biochemistry 1998; 37: 9230–9239
   PubMed Web of Science ®Google Scholar
• Ohndorf U.M., Rould M.A., He Q., Pabo C.O., Lippard S.J. Basis for Recognition of Cisplatin-Modified DNA by High-Mobility-Group Proteins. Nature 1999; 399: 708–712
   PubMed Web of Science ®Google Scholar
• Sancar A. Excision Repair in Mammalian Cells. J. Biol. Chem. 1995; 270: 15915–15918
   PubMed Web of Science ®Google Scholar
• Reardon J.T., Vaisman A., Chaney S.G., Sancar A. Efficient Nucleotide Excision Repair of Cisplatin, Oxaliplatin, and bis-Aceto-Amine-Dichloro-Cyclohexylamine-Platinum(IV) (JM216) Platinum Intrastrand DNA Diadducts. Cancer Res. 1999; 59: 3968–3971
   PubMed Web of Science ®Google Scholar
• Petersen L.N., Mamenta E.L., Stevsner T., Chaney S.G., Bohr V.A. Increased Gene Specific Repair of Cisplatin Induced Interstrand Crosslinks in Cisplatin Resistant Cell Lines, and Studies on Carrier Ligand Specificity. Carcinogenesis 1996; 17: 2597–2602
   PubMed Web of Science ®Google Scholar
• Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., Christen R.D., Howell S.B. The Role of Mismatch Repair in Platinum Drug Resistance. Cancer Res. 1996; 56: 4881–4886
   PubMed Web of Science ®Google Scholar
• Fink D., Zheng H., Nebel S., Norris P.S., Aebi S., Lin T.-P., Nehme A., Christen R.D., Haas M., MacLeod C.L., Howell S.B. In Vitro and In Vivo Resistance to Cisplatin in Cells that have Lost DNA Mismatch Repair. Cancer Res. 1997; 57: 1841–1845
   PubMed Web of Science ®Google Scholar
• Nehme A., Baskaran R., Aebi S., Fink D., Nebel S., Cenni B., Wang J.Y.J., Howell S.B., Christen R.D. Differential Induction of c-Jun NH2-Terminal Kinase and c-Abl Kinase in DNA Mismatch Repair-Proficient and Deficient Cells Exposed to Cisplatin. Cancer Res. 1997; 57: 3253–3257
   PubMed Web of Science ®Google Scholar
• Nehme A., Baskaran R., Nebel S., Fink D., Howell S.B., Wang J.Y.J., Christen R.D. Induction of JNK and c-Abl Signalling by Cisplatin and Oxaliplatin in Mismatch Repair-Proficient and -Deficient Cells. Br. J. Cancer 1999; 79(7–8)1104–1110
   PubMed Web of Science ®Google Scholar
• Gibbons G.R., Kaufmann W.K., Chaney S.G. Role of DNA Replication in Carrier-Ligand-Specific Resistance to Platinum Compounds in L1210 Cells. Carcinogenesis 1991; 12: 2253–2257
   PubMed Web of Science ®Google Scholar
• Mamenta E.L., Poma E.E., Kaufmann W.K., Delmastro D.A., Grady H.L., Chaney S.G. Enhanced Replicative Bypass of Platinum-DNA Adducts in Cisplatin-Resistant Human Ovarian Carcinoma Cell Lines. Cancer Res. 1994; 54: 3500–3505
   PubMed Web of Science ®Google Scholar
• Vaisman A., Lim S.E., Patrick S.M., Copeland W.C., Hinkle D.C., Turchi J.J., Chaney S.G. Effect of DNA Polymerases and High Mobility Group Protein 1 on the Carrier Ligand Specificity for Translesion Synthesis Past Platinum-DNA Adducts. Biochemistry 1999; 38: 11026–11039
   PubMed Web of Science ®Google Scholar
• Hoffmann J.S., Locker D., Viliani G., Leng M. HMG1 Protein Inhibits the Translesion Synthesis of the Major DNA Cisplatin Adduct by Cell Extracts. J. Mol. Biol. 1997; 270: 539–543
   PubMed Web of Science ®Google Scholar
• Huang J.C., Zamble D.B., Reardon J.T., Lippard S.J., Sancar A. HMG-Domain Proteins Specifically Inhibit the Repair of the Major DNA Adduct of the Anticancer Drug Cisplatin by Human Excision Nuclease. Proc. Natl Acad. Sci. USA 1994; 91: 10394–10398
   PubMed Web of Science ®Google Scholar
• Treiber D.K., Zhai X.Q., Jantzen H.M., Essigmann J.M. Cisplatin–DNA Adducts are Molecular Decoys for the Ribosomal RNA Transcription Factor hUBF (Human Upstream Binding Factor). Proc. Natl Acad. Sci. USA 1994; 91: 5672–5676
   PubMed Web of Science ®Google Scholar
• Trimmer E.E., Zamble D.B., Lippard S.J., Essigmann J.M. Human Testis-Determining Factor SRY Binds to the Major DNA Adduct of Cisplatin and a Putative Target Sequence with Comparable Affinities. Biochemistry 1998; 37: 352–362
   PubMed Web of Science ®Google Scholar
• Vichi P., Coin F., Renaud J.P., Vermeulen W., Hoeijmakers J.H.J., Moras D., Egly J.M. Cisplatin- and UV-Damaged DNA Lure the Basal Transcription Factor TFIID/TBP. EMBO J. 1997; 16: 7444–7456
   PubMed Web of Science ®Google Scholar
• Zhai X., Beckmann H., Jantzen H.-M., Essigmann J.M. Cisplatin–DNA Adducts Inhibit Ribosomal RNA Synthesis by Hijacking the Transcription Factor Human Upstream Binding Factor. Biochemistry 1998; 37: 16307–16315
   PubMed Web of Science ®Google Scholar
• Butour J.L., Mazard A.M., Macquet J.P. Kinetics of the Reaction of cis-Platinum Compounds with DNA In Vitro. Biochem. Biophys. Res. Commun. 1985; 133: 347–353
   PubMed Web of Science ®Google Scholar
• Pinto A.L., Lippard S.J. Binding of the Antitumor Drug cis-Diamminedichloroplatinum(II) (Cisplatin) to DNA. Biochim. Biophys. Acta 1985; 780: 167–180
   PubMed Web of Science ®Google Scholar
• Chaney S.G., Wyrick S., Till G.K. In Vitro Biotransformations of Tetrachloro(d,l-trans)-1,2-Diaminocyclohexaneplatinum(IV) (Tetraplatin) in Rat Plasma. Cancer Res. 1990; 50: 4539–4545
   PubMed Web of Science ®Google Scholar
• Gibbons G.R., Wyrick S., Chaney S.G. Rapid Reduction of Tetrachloro(d,l-trans)1,2-Diaminocyclohexaneplatinum(IV) (Tetraplatin) in RPMI 1640 Tissue Culture Medium. Cancer Res. 1989; 49: 1402–1407
   PubMed Web of Science ®Google Scholar
• Mauldin S.K., Gibbons G., Wyrick S.D., Chaney S.G. Intracellular Biotransformation of Platinum Compounds with the 1,2-Diaminocyclohexane Carrier Ligand in the L1210 Cell Line. Cancer Res. 1988; 48: 5136–5144
   PubMed Web of Science ®Google Scholar
• Luo F.R., Wyrick S.D., Chaney S.G. Cytotoxicity, Cellular Uptake, and Cellular Biotransformations of Oxaliplatin in Human Colon Carcinoma Cells. Oncol. Res. 1998; 10: 595–603
   PubMed Web of Science ®Google Scholar
• Mauldin S.K., Plescia M., Richard F.A., Wyrick S.D., Voyksner R.D., Chaney S.G. Displacement of the Bidentate Malonate Ligand from (d,l-trans-1,2-Diaminocyclohexane)Malonatoplatinum(II) by Physiologically Important Compounds In Vitro. Biochem. Pharmacol. 1988; 37: 3321–3333
   PubMed Web of Science ®Google Scholar
• Luo F.R., Yen T.Y., Wyrick S.D., Chaney S.G. High-Performance Liquid Chromatographic Separation of the Biotransformation Products of Oxaliplatin. J. Chromatogr. B 1999; 724: 345–356
   PubMedGoogle Scholar
• Mauldin S.K., Richard F.A., Plescia M., Wyrick S.D., Sancar A., Chaney S.G. High-Performance Liquid Chromatographic Separation of Platinum Complexes Containing the cis-1,2-Diaminocyclohexane Carrier Ligand. Anal. Biochem. 1986; 157: 129–143
   PubMed Web of Science ®Google Scholar
• Luo F.R., Wyrick S.D., Chaney S.G. Biotransformations of Oxaliplatin in Rat Blood In Vitro. J. Biochem. Mol. Toxicol. 1999; 13: 159–169
   PubMed Web of Science ®Google Scholar
• Holmes J., Stanko J., Varchenko M., Ding H., Madden V.J., Bagnell C.R., Wyrick S.D., Chaney S.G. Comparative Neurotoxicity of Oxaliplatin, Cisplatin, and Ormaplatin in a Wistar Rat Model. Toxicol. Sci. 1998; 46: 342–351
   PubMed Web of Science ®Google Scholar
• New P., Barohn R., O'Rourke T., Seharaseyan J., Mendell J.R., Sahenk Z. Neuropathy Following Ormaplatin Administration: Human and Laboratory Studies. Proc. Am. Soc. Clin. Oncol. 1993; 12: 155–160
   Google Scholar
• O'Rourke T.J., Weiss G.R., New P., Burris H.A., Rodriguez G., Eckhardt J., Hardy J., Kuhn J.G., Fields S., Clark G.M., Von Hoff D.D. Phase I Clinical Trial of Ormaplatin (Tetraplatin, NSC 363812). Anti-Cancer Drugs 1994; 5: 520–526
   PubMed Web of Science ®Google Scholar
• Luo F.R., Wyrick S.D., Chaney S.G. Pharmacokinetics and Biotransformations of Oxaliplatin in Comparison with Ormaplatin Following a Single Bolus Intravenous Injection in Rats. Cancer Chemother. Pharmacol. 1999; 44: 19–28
   PubMed Web of Science ®Google Scholar
• Petros W.P., Chaney S.G., Smith D.C., Fangmeier J., Sakata M., Brown T.D., Trump D.L. Pharmacokinetic and Biotransformation Studies of Ormaplatin in Conjunction with a Phase-I Clinical Trial. Cancer Chemother. Pharmacol. 1994; 33: 347–354
   PubMed Web of Science ®Google Scholar
• Luo F.R., Wyrick S.D., Chaney S.G. Comparative Neurotoxicity of Oxaliplatin, Ormaplatin, and Their Biotransformation Products Utilizing a Rat Dorsal Root Ganglia In Vitro Explant Culture Model. Cancer Chemother. Pharmacol. 1999; 44(1)29–38
   PubMed Web of Science ®Google Scholar
• Pendyala L., Creaven P.J. In Vitro Cytotoxicity, Protein Binding, Red Blood Cell Partitioning, and Biotransformation of Oxaliplatin. Cancer Res. 1993; 53: 5970–5976
   PubMed Web of Science ®Google Scholar
• Natarajan G., Malathi R., Holler E. Increased DNA Binding Activity of Cis-1,1-Cyclobutanedicarboxylatodiammineplatinum(II) (Carboplatin) in the Presence of Nucleophiles and Human Breast Cancer MCF-7 Cell Cytoplasmic Extracts: Activation Theory Revisited. Biochem. Pharmacol. 1999; 58: 1625–1629
   PubMed Web of Science ®Google Scholar
• Blommaert F.A., van Dijk-Knijnenburg H.C.M., Dijt F.J., Denengelse L., Baan R.A., Berends F., Fichtinger-Schepman A.M.J. Formation of DNA Adducts by the Anticancer Drug Carboplatin: Different Nucleotide Sequence Preferences In Vitro and In Cells. Biochemistry 1995; 34: 8474–8480
   PubMed Web of Science ®Google Scholar
• Fichtinger-Schepman A.M.J., van Dijk-Knijnenburg H.C.M., van der Velde-Visser S.D., Berends F., Baan R.A. Cisplatin and Carboplatin–DNA Adducts: Is Pt–AG the Cytotoxic Lesion?. Carcinogenesis 1995; 16: 2447–2453
   PubMed Web of Science ®Google Scholar
• McDougall S., Allen J. In Vitro Stability of [³H]-Oxaliplatin in Human Plasma Filtrate and Urine. 1998
   Google Scholar
• Kraker A.J., Moore C.W. Accumulation of cis-Diammine-Dichloroplatinum(II) and Platinum Analogues by Platinum-Resistant Murine Leukemia Cells In Vitro. Cancer Res. 1988; 48: 9–13
   PubMed Web of Science ®Google Scholar
• Sivestro L., Anal H., Sommer F., , et al. Comparative Effects of a New Platinum Analog (Trans-1-Diamine-Cyclohexane Oxalato-Platinum; l-OHP) with CDDP on Various Cells: Correlation with Intracellular Accumulation. Anticancer Res. 1990; 10–15: 1376
   Google Scholar
• Rixe O., Ortuzar W., Alvarez M., , et al. Oxaliplatin, Tetraplatin, Cisplatin, and Carboplatin: Spectrum of Activity in Drug-Resistant Cell Lines and in the Cell Lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem. Pharmacol. 1996; 52: 1855–1865
   PubMed Web of Science ®Google Scholar
• Fukuda M., Ohe Y., Kanzawa F., , et al. Evaluation of Novel Platinum Complexes, Inhibitors of Topoisomerase I and II in Non-small Cell Lung Cancer (NSCLC) Sublines Resistant to Cisplatin. Anticancer Res. 1995; 15: 393–398
   PubMed Web of Science ®Google Scholar
• Riccardi A., Ferlini C., Meco D., Mastrangelo R., Scambia G., Riccardi R. Antitumour Activity of Oxaliplatin in Neuroblastoma Cell Lines. Eur. J. Cancer 1999; 35(1)86–90
   PubMed Web of Science ®Google Scholar
• Dunn T.A., Schmoll H.J., Grünwald V., , et al. Comparative Cytotoxicity of Oxaliplatin and Cisplatin in Non-seminomatous Germ Cell Cancer Cell Lines. Invest. New Drugs 1997; 15: 109–114
   PubMed Web of Science ®Google Scholar
• Becouarn Y., Rougier P. Clinical Efficacy of Oxaliplatin Monotherapy: Phase II Trials in Advanced Colorectal Cancer. Semin. Oncol. 1998; 25(2, Suppl. 5)23–31
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E., Sastre J., Zaniboni A. Oxaliplatin as Single Agent in Previously Untreated Colorectal Carcinoma Patients: A Phase II Multicentric Study. Ann. Oncol. 1998; 9: 105–108
   PubMed Web of Science ®Google Scholar
• Machover D., Diaz-Rubio E., de Gramont A., , et al. Two Consecutive Phase II Studies of Oxaliplatin (l-OHP) for Treatment of Patients with Advanced Colorectal Carcinoma Who Were Resistant to Previous Treatment with Fluoropyrimidines. Ann. Oncol. 1996; 7: 95–98
   PubMed Web of Science ®Google Scholar
• Lévi F., Perpoint B., Garufi C., , et al. Oxaliplatin Activity Against Metastatic Colorectal Cancer. A Phase II Study of 5-Day Continuous Venous Infusion at Circadian Rhythm Modulated Rate. Eur. J. Cancer 1993; 29A: 1280–1284
   PubMed Web of Science ®Google Scholar
• Raymond E., Faivre S., Woynarowski J.M., , et al. Oxaliplatin: Mechanism of Action and Antineoplastic Activity. Semin. Oncol. 1998; 25(2, Suppl. 5)4–12
   PubMed Web of Science ®Google Scholar
• Pendyala L., Creaven P.J., Perez R., , et al. Intracellular Glutathione and Cytotoxicity of Platinum Complexes. Cancer Chemother. Pharmacol. 1995; 36–39: 271–278
   Web of Science ®Google Scholar
• Kidani Y., Noji M., Tashiro T. Antitumor Activity of Platinum(II) Complexes of 1,2-Diamino-Cyclohexane Isomers. Gann 1980; 71: 637–643
   PubMedGoogle Scholar
• Mathé G., Kidani Y., Noji M., , et al. Antitumor Activity of l-OHP in Mice. Cancer Lett. 1985; 27: 135–143
   PubMed Web of Science ®Google Scholar
• Tashiro T., Kawada Y., Sakurai Y., , et al. Antitumor Activity of a New Platinum Complex, Oxalato (trans-l-1,2-Diaminocyclohexane)Platinum (II): New Experimental Data. Biomed. Pharmacother. 1989; 43: 251–260
   PubMed Web of Science ®Google Scholar
• Mathé G., Kidani Y., Segiguchi M., , et al. Oxalato-Platinum or l-OHP, a Third-Generation Platinum Complex: An Experimental and Clinical Appraisal and Preliminary Comparison with Cis-Platinum and Carboplatinum. Biomed. Pharmacother. 1989; 43: 237–250
   PubMed Web of Science ®Google Scholar
• Noji M., Okamoto K., Kidani Y., , et al. Relation of Conformation to Antitumor Activity of Platinum(II) Complexes of 1,2-Cyclohexanediamine and 2-(Aminomethyl)Cyclohexylamine Isomers Against Leukemia P388. J. Med. Chem. 1981; 24: 508–515
   PubMed Web of Science ®Google Scholar
• Zeghari-Squalli N., Misset J.L., Cvitkovic E., , et al. Mechanism of the In Vitro Synergism Between SN38 and Oxaliplatin. Proc. Am. Assoc. Cancer Res. 1997; 38: A20
   Google Scholar
• Zeghari-Squalli N., Raymond E., Cvitkovic E., Goldwasser F. Cellular Pharmacology of the Combination of the DNA Topoisomerase I Inhibitor SN-38 and the Diaminocyclohexane Platinum Derivative Oxaliplatin. Clin. Cancer Res. 1999; 5(5)1189–1196
   PubMed Web of Science ®Google Scholar
• Raymond E., Buquet-Fagot F., Djelloul C., , et al. Antitumor Activity of Oxaliplatin in Combination with 5-Fluorouracil and the Thymidylate Synthase Inhibitor AG337 in Human Colon, Breast and Ovarian Cancers. Anti-Cancer Drugs 1997; 8: 876–885
   PubMed Web of Science ®Google Scholar
• Goldwasser F., Bozec L., Zeghari-Squalli N., Misset J.L. Cellular Pharmacology of the Combination of Oxaliplatin with Topotecan in the IGROV-1 Human Ovarian Cancer Cell Line. Anti-Cancer Drugs 1999; 10(2)195–201
   PubMed Web of Science ®Google Scholar
• Faivre S., Raymond E., Woynarowski J.M., Cvitkovic E. Supraadditive Effect of 2′,2′-Difluorodeoxycytidine (Gemcitabine) in Combination with Oxaliplatin in Human Cancer Cell Lines. Cancer Chemother. Pharmacol. 1999; 44(2)117–123
   PubMed Web of Science ®Google Scholar
• Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., Gamelin E. Clinical Pharmacokinetics of Oxaliplatin: A Critical Review. Clin. Cancer Res. 2000; 6: 1205–1218
   PubMed Web of Science ®Google Scholar
• Massari C., Brienza S., Rotarski M., Gastiaburu J., Misset J.L., Cupissol D., Alafaci E., Dutertre-Catella H., Bastian G. Pharmacokinetics of Oxaliplatin in Patients with Normal Versus Impaired Renal Function. Cancer Chemother. Pharmacol. 2000; 45(2)157–164
   PubMed Web of Science ®Google Scholar
• Extra J.-M., Marty M., Brienza S., , et al. Pharmacokinetics and Safety Profile of Oxaliplatin. Semin. Oncol. 1998; 25(2, Suppl. 5)13–22
   PubMed Web of Science ®Google Scholar
• Vermorken J.B., van der Vijgh W.J.F., Klein I., , et al. Pharmacokinetics of Free and Total Platinum Species After Rapid and Prolonged Infusions of Cisplatin. Clin. Pharmacol. Ther. 1986; 39: 136–144
   PubMed Web of Science ®Google Scholar
• Gamelin E., Le Bouil A., Boisdron-Cell M., , et al. Cumulative Pharmacokinetic Study of Oxaliplatin, Administered Every Three Weeks, Combined with 5-Fluorouracil in Colorectal Cancer Patients. Clin. Cancer Res. 1997; 3: 891–899
   PubMed Web of Science ®Google Scholar
• Levi F., Metzger G., Massari C., Milano G. Oxaliplatin: Pharmacokinetics and Chronopharmacological Aspects. Clin. Pharmacokinet. 2000; 38(1)1–21
   PubMed Web of Science ®Google Scholar
• Cvitkovic E. Ongoing and Unsaid on Oxaliplatin: the Hope. Br. J. Cancer 1998; 77: 8–11
   PubMed Web of Science ®Google Scholar
• Cvitkovic E., Bekradda M. Oxaliplatin: a New Therapeutic Option in Colorectal Cancer. Semin. Oncol. 1999; 26(6)647–662
   PubMed Web of Science ®Google Scholar
• Mathé G., Kidani Y., Triana K., , et al. A Phase I Trial of trans-1-Diaminocyclohexane Oxalato-Platinum (L-OHP). Biomed. Pharmacother. 1986; 40: 372–376
   PubMed Web of Science ®Google Scholar
• Extra J.M., Espie M., Calvo F., , et al. Phase I Study of Oxaliplatin in Patients with Advanced Cancer. Cancer Chemother. Pharmacol. 1990; 25: 299–303
   PubMed Web of Science ®Google Scholar
• Screnci D., McKeage M.J. Platinum Neurotoxicity: Clinical Profiles, Experimental Models and Neuroprotective Approaches. J. Inorg. Biochem. 1999; 77(1–2)105–110
   PubMed Web of Science ®Google Scholar
• Brienza S., Vignoud J., Itzhaki M., , et al. Oxaliplatin (l-OHP): Global Safety in 682 Patients (pts). Proc. Am. Soc. Clin. Oncol. 1995; 14: A513
   Google Scholar
• Larzilliere I., Brandissou S., Breton P., Lingoungou A., Gargot D., Ramain J.P., Harnois C. Anaphylactic Reaction to Oxaliplatin: a Case Report. Am. J. Gastroenterol. 1999; 94(11)3387–3388
   PubMed Web of Science ®Google Scholar
• Desrame J., Broustet H., Darodes de Tailly P., Girard D., Saissy J.M. Oxaliplatin-Induced Haemolytic Anaemia. Lancet 1999; 2(354)1179–1180
   Google Scholar
• Medioni J., Coulon M.A., Morere J.F., Hennebelle F., Piperno-Neumann S., Breau J.L. Anaphylaxis after Oxaliplatin. Ann. Oncol. 1999; 10(5)610
   PubMedGoogle Scholar
• Tournigand C., Maindrault-Goebel F., Louvet C., de Gramont A., Krulik M. Severe Anaphylactic Reactions to Oxaliplatin. Eur. J. Cancer 1998; 34(8)1297–1298
   PubMed Web of Science ®Google Scholar
• O'Brien M.E., Souberbielle B.E. Allergic Reactions to Cytotoxic Drugs—An Update. Ann. Oncol. 1992; 3(8)605–610
   PubMed Web of Science ®Google Scholar
• Dodds H.M., Bishop J.F., Rivory L.P. More About Irinotecan-Related Cholinergic Syndrome Induced by Coadministration of Oxaliplatin. J. Natl Cancer Inst. 1999; 6(91(1))91–92
   Google Scholar
• Rothenberg M.L. Efficacy and Toxicity of Irinotecan in Patients with Colorectal Cancer. Semin. Oncol. 1998; 25: 36–46
   PubMedGoogle Scholar
• Lévi F., Misset J.-L., Brienza S., , et al. A Chronopharmacologic Phase II Clinical Trial with 5-Fluorouracil, Folinic Acid, and Oxaliplatin Using an Ambulatory Multichannel Programmable Pump: High Antitumor Effectiveness Against Metastatic Colorectal Cancer. Cancer 1992; 69: 893–900
   PubMed Web of Science ®Google Scholar
• Lévi F., Dogliotti L., Perpoint B., , et al. A Multicenter Phase II Trial of Intensified Chronotherapy with Oxaliplatin (l-OHP), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in Patients (Pts) with Previously Untreated Metastatic Colorectal Cancer (MCC). Proc. Am. Soc. Clin. Oncol. 1997; 16: A945
   Google Scholar
• Lévi F.A., Zidani R., Vannetzel J.-M., , et al. Chronomodulated Versus Fixed-Infusion-Rate Delivery of Ambulatory Chemotherapy with Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients with Colorectal Cancer Metastases: A Randomized Multi-Institutional Trial. J. Natl Cancer Inst. 1994; 86: 1608–1617
   PubMed Web of Science ®Google Scholar
• Lévi F., Zidani R., Misset J.-L., , et al. Randomised Multicentre Trial of Chronotherapy with Oxaliplatin, Fluorouracil, and Folinic Acid in Metastatic Colorectal Cancer. Lancet 1997; 350: 681–686
   PubMed Web of Science ®Google Scholar
• Giacchetti S., Zidani R., Perpoint B., , et al. Phase III Trial of 5-Fluorouracil (5-FU), Folinic Acid (FA), with or without Oxaliplatin (OXA) in Previously Untreated Patients (Pts) with Metastatic Colorectal Cancer (MCC). Proc. Am. Soc. Clin. Oncol. 1997; 16: A805
   Google Scholar
• Brienza S., Bensmaine M.A., Soulie P., Louvet C., Gamelin E., Francois E., Ducreux M., Marty M., Andre T., de Braud F., Bleiberg H., Segal V., Itzhaki M., Cvitkovic E. Oxaliplatin Added to 5-Fluorouracil-Based Therapy (5-FU+/−FA) in the Treatment of 5-FU-Pretreated Patients with Advanced Colorectal Carcinoma (ACRC): Results from the European Compassionate-Use Program. Ann. Oncol. 1999; 10(11)1311–1316
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., Louvet C., Andre T., Carola E., Lotz J.P., Molitor J.L., Garcia M.L., Gilles-Amar V., Izrael V., Krulik M., de Gramont M. Oxaliplatin Added to the Simplified Bimonthly Leucovorin and 5-Fluorouracil Regimen as Second-Line Therapy for Metastatic Colorectal Cancer (FOLFOX6) GERCOR. Eur. J. Cancer 1999; 35(9)1338–1342
   PubMed Web of Science ®Google Scholar
• Levi F., Zidani R., Brienza S., Dogliotti L., Perpoint B., Rotarski M., Letourneau Y., Llory J.F., Chollet P., Le Rol A., Focan C. A Multicenter Evaluation of Intensified, Ambulatory, Chronomodulated Chemotherapy with Oxaliplatin, 5-Fluorouracil, and Leucovorin as Initial Treatment of Patients with Metastatic Colorectal Carcinoma. Int. Orgn Cancer Chronother. Cancer 1999; 15(85(12))2532–2540
   Google Scholar
• Bleiberg H., de Gramont A. Oxaliplatin Plus 5-Fluorouracil: Clinical Experience in Patients with Advanced Colorectal Cancer. Semin. Oncol. 1998; 25(2, Suppl. 5)32–39
   PubMed Web of Science ®Google Scholar
• Garufi C., Brienza S., BensmaÍne M.A., , et al. Addition of Oxaliplatin (l-OHP) to Chronomodulated (CM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) for Reversal of Acquired Chemoresistance in Patients with Advanced Colorectal Cancer (ACC). Proc. Am. Soc. Clin. Oncol. 1995; 14: A446
   Google Scholar
• Wasserman E., Cuvier C., Lokiec F., Goldwasser F., Kalla S., Mery-Mignard D., Ouldkaci M., Besmaine A., Dupont-Andre G., Mahjoubi M., Marty M., Misset J.L., Cvitkovic E. Combination of Oxaliplatin Plus Irinotecan in Patients with Gastrointestinal Tumors: Results of Two Independent Phase I Studies with Pharmacokinetics. J. Clin. Oncol. 1999; 17(6)1751–1759
   PubMed Web of Science ®Google Scholar
• Goldwasser F., Chouaki N., Buthaud X., Riofrio M., Gross M., Tigaud J.M., Cvitkovic E., Mignard D., Mahjoubi M., Misset J.L. CPT-11/Oxaliplatin Every Two Weeks: A Phase I Study in Patients with Advanced Digestive Tumors. Proc. Am. Soc. Clin. Oncol. 1998; 17: 242a
   Google Scholar
• Kemeny N., Tong W., Stockman J., Blanchette J., Saltz L. Phase I Trial of Weekly Oxaliplatin and Irinotecan in Previously Treated Patients with Metastatic Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 245a
   Google Scholar
• Scheithauer W., Kornek G.V., Raderer M., Valencak J., Weinlander G., Hejna M., Haider K., Kwasny W., Depisch D. Combined Irinotecan and Oxaliplatin Plus Granulocyte Colony-Stimulating Factor in Patients with Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer. J. Clin. Oncol. 1999; 17(3)902–906
   PubMed Web of Science ®Google Scholar
• Ivy S.P., Blatner G., Cheson B.D. Clinical Trials Referral Resource. Clinical Trials of Combination Regimens Containing Oxaliplatin. Oncology (Huntington) 1999; 13(8)1116–1118
   PubMedGoogle Scholar
• Personal communication, Dr Tillman Pearce, Director Medical, Business Unit Oncologie, Sanofi-Synthelabo.
   Google Scholar
• Gil-Delgado M.A., Bastian G., Guinet F., Benhammouda A., Rocher E.C., Antoine D., Coeffic H., Bismuth H., Khayat D. Phase I–II Trial and Pharmacokinetic Analysis of Oxaliplatin Plus 5-FU/Leucovorin Plus Irinotecan Combination in Advanced Colorectal Carcinoma. Proc. Am. Soc. Clin. Oncol. 1998; 17: 254a
   Google Scholar
• Diaz-Rubio E., Evans J., Tabernero J., Cassidy J., Sastre J., Lim J., Bissett D., Baelga J., Regueiro P. Phase I Study of Capecitabine in Combination with Oxaliplatin in Patients with Advanced Metastatic Solid Tumors. Proc. Am. Soc. Clin. Oncol. 2000; 19: 198a
   Google Scholar
• Garcia-Giron C., Feliu J., Vincent J.M., Madronal C., Fonseca E., Constela M., de las Heras B., Camps C., Dorta J., Iglesias J., Castro J., Lorenzo J., Gonzalez-Baron M. Phase II Trial of Oxaliplatin–Uft–Leucovorin Combination in First Line Treatment of Advanced Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 293a
   Google Scholar
• Armand J.P., Seymour L., Evans T.R. Raltitrexed (Tomudex) in Combination with Platinum-Based Agents and/or Anthracyclines: Preliminary Results of Phase I Clinical Trials. Eur. J. Cancer 1999; 35(Suppl. 1)S14–S18
   PubMedGoogle Scholar
• Fizazi K., Soria J.C., Bonnay M., Ruffie P., Ducreux M., LeChevalier T., Couturas O., Poterre M., Armand J.P. Phase I/II Dose-Finding and Pharmacokinetic Study of Tomudex in Combination with Oxaliplatin in Advanced Solid Tumors. Proc. Am. Soc. Clin. Oncol. 1998; 17: 638
   Google Scholar
• Fizazi K., Viala J., Daniel C., LeChevalier T., Fandi A., Robert L., Smith M., Sahmoud T., Ruffie P. Raltitrexed (Tomudex) and Oxaliplatin: An Active Out-Patient Regimen in Malignant Mesothelioma. Eur. J. Cancer 1999; 35(Suppl. 4)252
   Google Scholar
• Casaretti R., DeLucia L., DeVita F., Avallone A., Orditura M., Gravina A., D'Aniello R., Comella P., Catalano G., Comella G. Oxalipaltin+Tomudex and Levo-Folinic Acid+Fluorouracil Every 2 Weeks. A Dose Finding Study in Advanced Colorectal Carcinoma. Eur. J. Cancer 1999; 35(Suppl. 4)289
   PubMedGoogle Scholar
• Bennouna J., Seitz J.F., Paillot B., Gamelin E., Francois E., Conroy T., Raoul J.L., Becouanm Y., Cvitkovic F.B., Nasca S., Ychou M., Jacob J., Smith M., Douillard J.Y., Fandi A. Tomudex Plus Oxaliplatin in Previously Untreated Metastatic Colorectal Cancer Patients: An Active Combination. Eur. J. Cancer 1999; 35(Suppl. 4)75
   Google Scholar
• Van Custem E. Raltitrexed in Combination Treatment for Colorectal Cancer: New Perspectives. Eur. J. Cancer 1999; 35(Suppl. 1)S1–S2
   Google Scholar
• Jackman A.L., Kimbell R., Ford H.E. Combination of Raltitrexed with Other Cytotoxic Agents: Rationale and Preclinical Observations. Eur J. Cancer 1999; 35(Suppl. 1)S3–S8
   PubMedGoogle Scholar
• Mavroudis D., Agelaki S., Kalbakis K., Kouroussis Ch., Kakolyris S., Androulakis N., Souglakos J., Vardakis N., Samonis G., Georgoulias V. A Dose Finding and Toxicity Study of the Gemcitabine–Oxaliplatin Combination in Patients with Advanced Solid Tumors. Eur. J. Cancer 1999; 35(Suppl. 4)289
   PubMedGoogle Scholar
• Klapdor R., Svendsen J., Seutter R., Fenner C. Combination Therapy with Oxaliplatin+Gemcitabine in Advanced Pancreatic Cancer. Eur. J. Cancer 1999; 35(Suppl. 4)146
   Google Scholar
• Buchele T., Grothey A., Voigt W., Kegel T., Rie C., Wunderlich D., Schmoll H.J. Biweekly Docetaxel, Gemcitabine, Coxaliplatin in Heavily Pretreated Patients with Solid Tumors—Preliminary Results of a Phase I Study. Eur. J. Cancer 1999; 35(Suppl. 4)288
   Google Scholar
• Mani S., Gordon G., Vogelzang N.J., Bertucci D.S., Schilsky R.L., Stadler W.M., Ratain M.J. A Phase I Trial of Continuous Infusion 5-FU and Weekly Gemcitabine: Updated Results of an Active Combination for Renal Cell, Hepatocellular and Colon Cancer. Ann. Oncol. 1998; 2: 632
   Google Scholar
• Correale P., Cerretani D., Petroli R., Marsili S., Pozzessere D., Giorgi G., Francini G. Gemcitabine (dFdC) Affects 5-Flurouracil (5-FU) Pharmacokinetics in Cancer Patients. Proc. Am. Assoc. Cancer Res. 1999; 40: 384
   Google Scholar
• Kouroussis Ch., Androuliakis N., Kalbakis K., Kakolyris S., Mavroudis D., Agelaki S., Souglakos J., Vardakis N., Samonis G., Georgoulias V. A Phase I Study of Docetaxel and Oxaliplatin as Frontline Treatment in Metastatic Breast Cancer and Nonsmall Cell Lung Cancer: Preliminary Results. Eur. J. Cancer 1999; 35(Suppl. 4)293
   Google Scholar
• Faivre S., Kalla S., Cvitkovic E., Bourdon O., Hauteville D., Dourte L.M., Bensmaine M.A., Itzhaki M., Marty M., Extra J.M. Oxaliplatin and Paclitaxel Combination in Patients with Platinum-Pretreated Ovarian Carcinoma: An Investigator-Originated Compassionate-Use Experience. Ann. Oncol. 1999; 10(9)1125–1128
   PubMed Web of Science ®Google Scholar
• Fumuleau P., Gamelin E., Misset J.L., Delalogue S., Ripoche V., Kayitalire V. A Phase I Study of the Multitargetted Antifolate (MTA)(LY 231514) in Combination with Oxaliplatin in Metastatic Solid Tumors. Eur. J. Cancer 1999; 35(Suppl. 4)292
   Google Scholar
• DeCremoux H., Bekradda M., Monnet I., Soulie P., Saltiel S., Misset J.L., Fandi M.A., Bensmaine M.A., Cvitkovic E. Preliminary Report on Oxaliplatin/Navelbine Phase I/II Multicentric Trial in Patients with Advanced Nonsmall Cell Lung Cancer (NSCLC): An Active Combination. Proc. Am. Soc. Clin. Oncol. 1998; 17: 481a
   Google Scholar
• Bokemeyer C., Kollmannsberger C., Harstrick A., Beyer J., Gerl A., Casper J., Metzner B., Hartmann J.T., Schmoll H.J., Kanz L. Treatment of Patients with Cisplatin-Refractory Testicular Germ-Cell Cancer. German Testicular Cancer Study Group (GTCSG). Int. J. Cancer 1999; 83(6)848–851
   PubMed Web of Science ®Google Scholar
• Soulie P., Garrino C., Bensmaine M.A., Bekradda M., Brain E., Di Palma M., Goupil A., Misset J.L., Cvitkovic E. Antitumoral Activity of Oxaliplatin/Cisplatin-Based Combination Therapy In Cisplatin-Refractory Germ Cell Cancer Patients. J. Cancer Res. Clin. Oncol. 1999; 125(12)707–711
   PubMed Web of Science ®Google Scholar
• Hess S., Blackstock W. Oxaliplatin: In Vitro and In Vivo Evidence of Its Radiation Sensitizing Activity—Preclinical Observations Relevant to Ongoing Clinical Trials. Proc. Am. Assoc. Cancer Res. 2000; 41: 53
   Google Scholar
• Lawley P.D., Phillips D.H. DNA Adducts from Chemotherapeutic Agents. Mutat. Res. 1996; 355: 13–40
   PubMed Web of Science ®Google Scholar
• Reed E. Platinum-DNA Adduct, Nucleotide Excision Repair and Platinum Based Anti-Cancer Chemotherapy. Cancer Treat. Rev. 1998; 24: 331–344
   PubMed Web of Science ®Google Scholar
• de Laat W.L., Jaspers N.G., Hoeijmakers J.H. Molecular Mechanism of Nucleotide Excision Repair. Genes Dev. 1999; 13: 768–785
   PubMed Web of Science ®Google Scholar
• Wood R.D. Nucleotide Excision Repair in Mammalian Cells. J. Biol. Chem. 1997; 272: 23465–23468
   PubMed Web of Science ®Google Scholar
• Roy R., Adamczewski J.P., Seroz T., Vermeulen W., Tassan J.P., Schaeffer L., Nigg E.A., Hoeijmakers J.H., Egly J.M. The MO15 Cell Cycle Kinase Is Associated with the TFIIH Transcription—DNA Repair Factor. Cell 1994; 79: 1093–1101
   PubMed Web of Science ®Google Scholar
• Zhen W., Evans M.K., Haggerty C.M., Bohr V.A. Deficient Gene Specific Repair of Cisplatin-Induced Lesions in Xeroderma Pigmentosum and Fanconi's Anemia Cell Lines. Carcinogenesis 1993; 14: 919–924
   PubMed Web of Science ®Google Scholar
• Jones J.C., Zhen W.P., Reed E., Parker R.J., Sancar A., Bohr V.A. Gene-Specific Formation and Repair of Cisplatin Intrastrand Adducts and Interstrand Cross-Links in Chinese Hamster Ovary Cells. J. Biol. Chem. 1991; 266: 7101–7107
   PubMed Web of Science ®Google Scholar
• States J.C., Reed E. Enhanced XPA mRNA Levels in Cisplatin-Resistant Human Ovarian Cancer Are Not Associated with XPA Mutations or Gene Amplification. Cancer Lett. 1996; 108: 233–237
   PubMed Web of Science ®Google Scholar
• Zeng-Rong N., Paterson J., Alpert L., Tsao M.S., Viallet J., Alaoui-Jamali M.A. Elevated DNA Repair Capacity Is Associated with Intrinsic Resistance of Lung Cancer to Chemotherapy. Cancer Res. 1995; 55: 4760–4764
   PubMed Web of Science ®Google Scholar
• Chao C.C. Cross-Resistance to Cis-Diamminedichloroplatinum(II) of a Multidrug-Resistant Lymphoma Cell Line Associated with Decreased Drug Accumulation and Enhanced DNA Repair. Eur. J. Pharmacol. 1996; 305: 213–222
   PubMed Web of Science ®Google Scholar
• Chao C.C. Enhanced Excision Repair of DNA Damage Due to cis-Diamminedichloroplatinum(II) in Resistant Cervix Carcinoma HeLa Cells. Eur. J. Pharmacol. 1994; 268: 347–355
   PubMed Web of Science ®Google Scholar
• Eastman A., Schulte N. Enhanced DNA Repair as a Mechanism of Resistance to cis-Diamminedichloroplatinum(II). Biochemistry 1988; 27: 4730–4734
   PubMed Web of Science ®Google Scholar
• Lee K.B., Parker R.J., Bohr V., Cornelison T., Reed E. Cisplatin Sensitivity/Resistance in UV Repair-Deficient Chinese Hamster Ovary Cells of Complementation Groups 1 and 3. Carcinogenesis 1993; 14: 2177–2180
   PubMed Web of Science ®Google Scholar
• Li Q., Bostick-Bruton F., Reed E. Effect of Interleukin-1 Alpha and Tumour Necrosis Factor-Alpha on Cisplatin-Induced ERCC-1 mRNA Expression in a Human Ovarian Carcinoma Cell Line. Anticancer Res. 1998; 18: 2283–2287
   PubMed Web of Science ®Google Scholar
• Li Q., Gardner K., Zhang L., Tsang B., Bostick-Bruton F., Reed E. Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells. J. Biol. Chem. 1998; 273: 23419–23425
   PubMed Web of Science ®Google Scholar
• Taverna P., Hansson J., Scanlon K.J., Hill B.T. Gene Expression in X-Irradiated Human Tumour Cell Lines Expressing Cisplatin Resistance and Altered DNA Repair Capacity. Carcinogenesis 1994; 15: 2053–2056
   PubMed Web of Science ®Google Scholar
• Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. Messenger RNA Levels of XPAC and ERCC1 in Ovarian Cancer Tissue Correlate with Response to Platinum-Based Chemotherapy. J. Clin. Invest. 1994; 94: 703–708
   PubMed Web of Science ®Google Scholar
• Koberle B., Masters J.R., Hartley J.A., Wood R.D. Defective Repair of Cisplatin-Induced DNA Damage Caused by Reduced XPA Protein in Testicular Germ Cell Tumours. Curr. Biol. 1999; 9: 273–276
   PubMed Web of Science ®Google Scholar
• Damia G., Guidi G., D'Incalci M. Expression of Genes Involved in Nucleotide Excision Repair and Sensitivity to Cisplatin and Melphalan in Human Cancer Cell Lines. Eur. J. Cancer 1998; 34: 1783–1788
   PubMed Web of Science ®Google Scholar
• Cleaver J.E., States J.C. The DNA Damage-Recognition Problem in Human and Other Eukaryotic Cells: The XPA Damage Binding Protein. Biochem. J. 1997; 328: 1–12
   PubMed Web of Science ®Google Scholar
• de Vries A., van Oostrom C.T., Hofhuis F.M., Dortant P.M., Berg R.J., de Gruijl F.R., Wester P.W., van Kreijl C.F., Capel P.J., van Steeg H., , et al. Increased Susceptibility to Ultraviolet-B and Carcinogens of Mice Lacking the DNA Excision Repair Gene XPA. Nature 1995; 377: 169–173
   PubMed Web of Science ®Google Scholar
• Wilson D.M.R., Thompson L.H. Life Without DNA Repair [Comment]. Proc. Natl Acad. Sci. USA 1997; 94: 12754–12757
   PubMed Web of Science ®Google Scholar
• Klungland A., Hoss M., Gunz D., Constantinou A., Clarkson S.G., Doetsch P.W., Bolton P.H., Wood R.D., Lindahl T. Base Excision Repair of Oxidative DNA Damage Activated by XPG Protein. Mol. Cell 1999; 3: 33–42
   PubMed Web of Science ®Google Scholar
• Nakane H., Takeuchi S., Yuba S., Saijo M., Nakatsu Y., Murai H., Nakatsuru Y., Ishikawa T., Hirota S., Kitamura Y., , et al. High Incidence of Ultraviolet-B- or Chemical-Carcinogen-Induced Skin Tumours in Mice Lacking the Xeroderma Pigmentosum Group A Gene. Nature 1995; 377: 165–168
   PubMed Web of Science ®Google Scholar
• Reese D.M., Slamon D.J. HER-2/neu Signal Transduction in Human Breast and Ovarian Cancer. Stem Cells 1997; 15: 1–8
   PubMed Web of Science ®Google Scholar
• Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Hung M.C., Lau Y.K. Basic Science of HER-2/neu: A Review. Semin. Oncol. 1999; 26: 51–59
   PubMed Web of Science ®Google Scholar
• Hynes N.E., Stern D.F. The Biology of erbB-2/neu/HER-2 and Its Role in Cancer. Biochim. Biophys. Acta 1994; 1198: 165–184
   PubMed Web of Science ®Google Scholar
• Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., Fox J.A. Nonclinical Studies Addressing the Mechanism of Action of Trastuzumab (Herceptin). Semin. Oncol. 1999; 26: 60–70
   PubMed Web of Science ®Google Scholar
• Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells. Oncogene 1994; 9: 1829–1838
   PubMed Web of Science ®Google Scholar
• Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of Human Breast Cancer Xenografts on Therapy with Humanized Monoclonal Antibody to HER-2 Receptor and DNA-Reactive Drugs. Oncogene 1998; 17: 2235–2249
   PubMed Web of Science ®Google Scholar
• Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., Coombs D., Baly D., Kabbinavar F., Slamon D. Inhibitory Effects of Combinations of HER-2/neu Antibody and Chemotherapeutic Agents Used for Treatment of Human Breast Cancers. Oncogene 1999; 18: 2241–2251
   PubMed Web of Science ®Google Scholar
• Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., Baly D., Baughman S.A., Twaddell T., Glaspy J.A., Slamon D.J. Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER2/neu Monoclonal Antibody Plus Cisplatin in Patients with HER-2/neuOverexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. J. Clin. Oncol. 1998; 16: 2659–2671
   PubMed Web of Science ®Google Scholar
• Pegram M.D., Slamon D.J. Combination Therapy with Trastuzumab (Herceptin) and Cisplatin for Chemoresistant Metastatic Breast Cancer: Evidence for Receptor-Enhanced Chemosensitivity. Semin. Oncol. 1999; 26: 89–95
   PubMed Web of Science ®Google Scholar
• Tsai C.M., Chang K.T., Perng R.P., Mitsudomi T., Chen M.H., Kadoyama C., Gazdar A.F. Correlation of Intrinsic Chemoresistance of Non-small-Cell Lung Cancer Cell Lines with HER-2/neu Gene Expression But Not with Ras Gene Mutations. J. Natl Cancer Inst. 1993; 85: 897–901
   PubMed Web of Science ®Google Scholar
• Tsai C.M., Yu D., Chang K.T., Wu L.H., Perng R.P., Ibrahim N.K., Hung M.C. Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer Cells. J. Natl Cancer Inst. 1995; 87: 682–684
   PubMed Web of Science ®Google Scholar
• Pegram M.D., Finn R.S., Arzoo K., Beryt M., Pietras R.J., Slamon D.J. The Effect of HER-2/neu Overexpression on Chemotherapeutic Drug Sensitivity in Human Breast and Ovarian Cancer Cells. Oncogene 1997; 15: 537–547
   PubMed Web of Science ®Google Scholar
• Dixit M., Yang J.L., Poirier M.C., Price J.O., Andrews P.A., Arteaga C.L. Abrogation of Cisplatin-Induced Programmed Cell Death in Human Breast Cancer Cells by Epidermal Growth Factor Antisense RNA [see Comments]. J. Natl Cancer Inst. 1997; 89: 365–373
   PubMed Web of Science ®Google Scholar
• Zhang L., Hung M.C. Sensitization of HER-2/neuOverexpressing Non-Small Cell Lung Cancer Cells to Chemotherapeutic Drugs by Tyrosine Kinase Inhibitor Emodin. Oncogene 1996; 12: 571–576
   PubMed Web of Science ®Google Scholar
• Yen L., Nie Z.R., You X.L., Richard S., Langton-Webster B.C., Alaoui-Jamali M.A. Regulation of Cellular Response to Cisplatin-Induced DNA Damage and DNA Repair in Cells Overexpressing p185(erbB-2) Is Dependent on the Ras Signaling Pathway. Oncogene 1997; 14: 1827–1835
   PubMed Web of Science ®Google Scholar
• Tsai C.M., Levitzki A., Wu L.H., Chang K.T., Cheng C.C., Gazit A., Perng R.P. Enhancement of Chemosensitivity by Tyrphostin AG825 in High-p185(neu) Expressing Non-small Cell Lung Cancer Cells. Cancer Res. 1996; 56: 1068–1074
   PubMed Web of Science ®Google Scholar
• You X.L., Yen L., Zeng-Rong N., Al Moustafa A.E., Alaoui-Jamali M.A. Dual Effect of erbB-2 Depletion on the Regulation of DNA Repair and Cell Cycle Mechanisms in Non-small Cell Lung Cancer Cells. Oncogene 1998; 17: 3177–3186
   PubMed Web of Science ®Google Scholar
• Chang L.C., Sheu H.M., Huang Y.S., Tsai T.R., Kuo K.W. A Novel Function of Emodin: Enhancement of the Nucleotide Excision Repair of UV- and Cisplatin-Induced DNA Damage in Human Cells. Biochem. Pharmacol. 1999; 58: 49–57
   PubMed Web of Science ®Google Scholar
• Jiang H., Yang L.Y. Cell Cycle Checkpoint Abrogator UCN-01 Inhibits DNA Repair: Association with Attenuation of the Interaction of XPA and ERCC1 Nucleotide Excision Repair Proteins [In Process Citation]. Cancer Res. 1999; 59: 4529–4534
   PubMed Web of Science ®Google Scholar
• Krueger I., Mullenders L.H., Hartwig A. Nickel(II) Increases the Sensitivity of V79 Chinese Hamster Cells Towards Cisplatin and Transplatin by Interference with Distinct Steps of DNA Repair. Carcinogenesis 1999; 20: 1177–1184
   PubMed Web of Science ®Google Scholar
• Li L., Liu X., Glassman A.B., Keating M.J., Stros M., Plunkett W., Yang L.Y. Fludarabine Triphosphate Inhibits Nucleotide Excision Repair of Cisplatin-Induced Dna Adducts In Vitro. Cancer Res. 1997; 57: 1487–1494
   PubMed Web of Science ®Google Scholar
• Ohmori T., Yang J.L., Price J.O., Arteaga C.L. Blockade of Tumor Cell Transforming Growth Factor-Betas Enhances Cell Cycle Progression and Sensitizes Human Breast Carcinoma Cells to Cytotoxic Chemotherapy. Exp. Cell Res. 1998; 245: 350–359
   PubMed Web of Science ®Google Scholar
• Lu Y., Mani S., Agarwal S., States J.C., Bregman D.B. Mixed Backbone Oligonucleotides Targeting the Nucleotide Excision Repair Protein XPA Potentiate Cisplatin Cytotoxicity. Cancer 2000, abstr # 4085
   Google Scholar
• Vaisman A., Masutari C., Hanaoka F., Chaney S.G. Efficient Translesion Replication Past Oxaliplatin and Cisplation GPG Adducts by Human DNA Polymerase. Biochemistry 2000; 39: 4575–4580
   PubMed Web of Science ®Google Scholar